MiRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Põlajeva, Jelena ^a   Swartling, Fredrik J ^a   Jiang, Yiwen ^a   Singh, Umashankar ^a   Pietras, Kristian ^b   Uhrbom, Lene ^a   Westermark, Bengt ^a   Roswall, Pernilla ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glioma; Imatinib (Gleevec); miR 21; miRNA; PDGF BB; RCAS tv a; SOX2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; IMATINIB; MICRORNA 21; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; RAPAMYCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CANCER INHIBITION; EMBRYO; EMBRYO DEVELOPMENT; FIBROBLAST; GENE EXPRESSION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NEWBORN; NONHUMAN; NORTHERN BLOTTING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CHICKENS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-SIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84870660623     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-378     Document Type: Article

References (56)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866. 10.1038/nrc1997, 17060945.
3. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269. 10.1038/nrc1840, 16557279.
4. Ambros V. The functions of animal microRNAs. Nature 2004, 431(7006):350-355. 10.1038/nature02871, 15372042.
5. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010, 17(2):215-220. 10.1038/cdd.2009.69, 19498445.
6. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10(10):704-714. 10.1038/nrg2634, 3467096, 19763153.
7. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179. 10.1146/annurev.med.59.053006.104707, 19630570.
8. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010, 20(5):589-599. 10.1101/gr.098046.109, 2860161, 20439436.
9. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65(14):6029-6033. 10.1158/0008-5472.CAN-05-0137, 16024602.
10. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
11. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109(11):4944-4951. 10.1182/blood-2006-12-062398, 17327404.
12. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010, 18(3):282-293. 10.1016/j.ccr.2010.08.013, 2971666, 20832755.
13. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467(7311):86-90. 10.1038/nature09284, 20693987.
14. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003, 361(9354):323-331. 10.1016/S0140-6736(03)12328-8, 12559880.
15. Hegi ME, Murat A, Lambiv WL, Stupp R. Brain tumors: molecular biology and targeted therapies. Ann Oncol 2006, 17(Suppl 10):x191-x197. 10.1093/annonc/mdl259, 17018723.
16. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602(1):73-87.
17. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52(11):3213-3219.
18. Lubitz W, Westermark B, Peterson PA. Surface glycoproteins of normal and neoplastic glia cells in culture. Int J Cancer 1980, 25(1):53-58. 10.1002/ijc.2910250107, 7399745.
19. Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, Ostman A. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006, 25(35):4913-4922. 10.1038/sj.onc.1209497, 16547494.
20. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968, 74(4):465-486.
21. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000, 25(1):55-57. 10.1038/75596, 10802656.
22. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 1998, 95(3):1218-1223. 10.1073/pnas.95.3.1218, 18724, 9448312.
23. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91(5):649-659. 10.1016/S0092-8674(00)80452-3, 9393858.
24. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413(6851):83-86. 10.1038/35092584, 11544530.
25. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85(1):27-37. 10.1016/S0092-8674(00)81079-X, 8620534.
26. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001, 413(6851):86-91. 10.1038/35092592, 11544531.
27. Singh U, Roswall P, Uhrbom L, Westermark B. CGGBP1 regulates cell cycle in cancer cells. BMC Mol Biol 2011, 12:28. 10.1186/1471-2199-12-28, 3142506, 21733196.
28. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998, 12(23):3675-3685. 10.1101/gad.12.23.3675, 317252, 9851974.
29. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, Uhrbom L, Westermark B. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA 2004, 101(31):11334-11337. 10.1073/pnas.0402716101, 509203, 15273287.
30. Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF, Carrel S. Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol 1981, 53(1):21-28. 10.1007/BF00697180, 7211194.
31. Ferletta M, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, Westermark B. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer 2011, 129(1):45-60. 10.1002/ijc.25647, 20824710.
32. Fael Al-Mayhani TM, Ball SL, Zhao JW, Fawcett J, Ichimura K, Collins PV, Watts C. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 2009, 176(2):192-199. 10.1016/j.jneumeth.2008.07.022, 19215724.
33. Jiang Y, Boije M, Westermark B, Uhrbom L. PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 2011, 13(6):492-503. 3114243, 21677873.
34. Ferletta M, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, Westermark B. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer 2010, 129(1):45-60.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
36. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003, 17(1):126-140. 10.1101/gad.224503, 195970, 12514105.
37. Vue TY, Aaker J, Taniguchi A, Kazemzadeh C, Skidmore JM, Martin DM, Martin JF, Treier M, Nakagawa Y. Characterization of progenitor domains in the developing mouse thalamus. J Comp Neurol 2007, 505(1):73-91. 10.1002/cne.21467, 17729296.
38. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, Alvarez-Buylla A. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006, 51(2):187-199. 10.1016/j.neuron.2006.06.012, 16846854.
39. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006, 232(2):139-147. 10.1016/j.canlet.2005.02.002, 16139423.
40. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 2007, 26(43):6289-6296. 10.1038/sj.onc.1210455, 17438529.
41. Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD, Rowitch DH. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004, 63(5):499-509.
42. Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 2009, 28(23):2266-2275. 10.1038/onc.2009.76, 19421151.
43. Bani-Yaghoub M, Tremblay RG, Lei JX, Zhang D, Zurakowski B, Sandhu JK, Smith B, Ribecco-Lutkiewicz M, Kennedy J, Walker PR, et al. Role of Sox2 in the development of the mouse neocortex. Dev Biol 2006, 295(1):52-66. 10.1016/j.ydbio.2006.03.007, 16631155.
44. Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003, 6(11):1162-1168. 10.1038/nn1131, 14517545.
45. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009, 27(1):40-48. 10.1634/stemcells.2008-0493, 18948646.
46. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
47. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63(18):5821-5828.
48. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760. 10.1038/nature05236, 17051156.
49. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67. 10.1186/1476-4598-5-67, 1697823, 17140455.
50. Buckley NJ, Johnson R, Sun YM, Stanton LW. Is REST a regulator of pluripotency?. Nature 2009, 457(7233):E5-6. discussion E7.
51. Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H, Majumder S. REST maintains self-renewal and pluripotency of embryonic stem cells. Nature 2008, 453(7192):223-227. 10.1038/nature06863, 2830094, 18362916.
52. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011, 307(1):26-36. 10.1016/j.canlet.2011.03.012, 3104092, 21463919.
53. Du J, Yang S, An D, Hu F, Yuan W, Zhai C, Zhu T. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res 2009, 19(4):487-496. 10.1038/cr.2009.34, 19308091.
54. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009, 106(29):12085-12090. 10.1073/pnas.0905234106, 2715493, 19597153.
55. Shao M, Rossi S, Chelladurai B, Shimizu M, Ntukogu O, Ivan M, Calin GA, Matei D. PDGF induced microRNA alterations in cancer cells. Nucleic Acids Res 2011, 39(10):4035-4047. 10.1093/nar/gkq1305, 3105413, 21266476.
56. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110. 10.1016/j.ccr.2009.12.020, 2818769, 20129251.